HealthEquity Management

Management criteria checks 3/4

HealthEquity's CEO is Jon Kessler, appointed in Feb 2014, has a tenure of 10.17 years. total yearly compensation is $13.40M, comprised of 5.2% salary and 94.8% bonuses, including company stock and options. directly owns 0.45% of the company’s shares, worth €29.28M. The average tenure of the management team and the board of directors is 2.7 years and 7.6 years respectively.

Key information

Jon Kessler

Chief executive officer

US$13.4m

Total compensation

CEO salary percentage	5.2%
CEO tenure	10.2yrs
CEO ownership	0.5%
Management average tenure	2.7yrs
Board average tenure	7.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jon Kessler's remuneration changed compared to HealthEquity's earnings?
Date	Total Compensation	Salary	Company Earnings
Jan 31 2024	n/a	n/a	US$56m
Oct 31 2023	n/a	n/a	US$29m
Jul 31 2023	n/a	n/a	US$13m
Apr 30 2023	n/a	n/a	-US$8m
Jan 31 2023	US$13m	US$700k	-US$26m
Oct 31 2022	n/a	n/a	-US$59m
Jul 31 2022	n/a	n/a	-US$62m
Apr 30 2022	n/a	n/a	-US$55m
Jan 31 2022	US$10m	US$700k	-US$44m
Oct 31 2021	n/a	n/a	-US$6m
Jul 31 2021	n/a	n/a	US$723k
Apr 30 2021	n/a	n/a	US$4m
Jan 31 2021	US$9m	US$667k	US$9m
Oct 31 2020	n/a	n/a	US$3m
Jul 31 2020	n/a	n/a	-US$20m
Apr 30 2020	n/a	n/a	-US$332k
Jan 31 2020	US$5m	US$500k	US$40m
Oct 31 2019	n/a	n/a	US$53m
Jul 31 2019	n/a	n/a	US$90m
Apr 30 2019	n/a	n/a	US$93m
Jan 31 2019	US$5m	US$483k	US$74m
Oct 31 2018	n/a	n/a	US$67m
Jul 31 2018	n/a	n/a	US$61m
Apr 30 2018	n/a	n/a	US$56m
Jan 31 2018	US$4m	US$400k	US$47m

Compensation vs Market: Jon's total compensation ($USD13.40M) is above average for companies of similar size in the German market ($USD3.42M).

Compensation vs Earnings: Jon's compensation has been consistent with company performance over the past year.

CEO

Jon Kessler (55 yo)

10.2yrs

Tenure

US$13,400,167

Compensation

Mr. Jon Kessler is a Member of the Board of Managers at HealthEquity Advisors, LLC. He has been the Chief Executive Officer and President of HealthEquity, Inc. since February 2014. Mr. Kessler founded Wage...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jon Kessler	President	10.2yrs	US$13.40m	0.45% $ 29.3m
Stephen Neeleman	Founder & Vice Chairman	21.4yrs	US$2.79m	0.96% $ 61.6m
Elimelech Rosner	Executive VP & CTO	2.1yrs	US$12.51m	0.011% $ 706.9k
James Lucania	CFO & Executive VP	less than a year	no data	no data
Angelique Hill	Executive Vice President of Operations	6yrs	no data	no data
Richard Putnam	Vice President of Investor Relations	no data	no data	no data
Delano Ladd	Executive VP	7.6yrs	US$1.53m	0.043% $ 2.8m
Steve Lindsay	Executive Vice President of Sales & Relationship Management	2.7yrs	no data	no data
Brad Bennion	Senior Vice President of Corporate Development	7yrs	no data	no data
Tia Padia	Executive VP & Chief Marketing Officer	2.3yrs	no data	no data
Cheryl King	Executive VP & Chief People Officer	less than a year	no data	no data
Kamesh Tumsi	Senior VP & Head of Product	1.4yrs	no data	no data

2.7yrs

Average Tenure

54.5yo

Average Age

Experienced Management: 2HE's management team is considered experienced (2.7 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Jon Kessler	President	15.1yrs	US$13.40m	0.45% $ 29.3m
Stephen Neeleman	Founder & Vice Chairman	21.4yrs	US$2.79m	0.96% $ 61.6m
Adrian Dillon	Independent Director	7.6yrs	US$375.50k	0.059% $ 3.8m
Robert Selander	Independent Non-Executive Chairman	8.6yrs	US$440.50k	0.049% $ 3.2m
Paul Black	Independent Director	1.6yrs	US$191.81k	0.00071% $ 45.8k
Evelyn Dilsaver	Independent Director	9.7yrs	US$363.00k	0.034% $ 2.2m
Frank Corvino	Independent Director	9.8yrs	US$350.50k	0.0048% $ 308.9k
Stuart Parker	Independent Director	3.3yrs	US$343.00k	0.037% $ 2.4m
Gayle Wellborn	Independent Director	6.7yrs	US$363.00k	0.014% $ 899.7k
Debra McCowan	Independent Director	6yrs	US$353.00k	0.0082% $ 529.5k
Rajesh Natarajan	Independent Director	1.9yrs	US$278.11k	0.0057% $ 370.9k

7.6yrs

Average Tenure

62yo

Average Age

Experienced Board: 2HE's board of directors are considered experienced (7.6 years average tenure).

HealthEquity Management

Management criteria checks 3/4

Key information

Recent management updates

HealthEquity, Inc., Annual General Meeting, Jun 27, 2024

HealthEquity, Inc. Announces the Termination of the Employment of Larry Trittschuh, Executive Vice President and Chief Security Officer

Executive VP & CTO recently sold €607k worth of stock

HealthEquity, Inc. Announces Change of CFO

Independent Director recently sold €305k worth of stock

Independent Director recently sold €312k worth of stock

Recent updates

HealthEquity, Inc., Annual General Meeting, Jun 27, 2024

Full year 2024 earnings released: EPS: US$0.65 (vs US$0.31 loss in FY 2023)

HealthEquity, Inc. to Report Q4, 2024 Results on Mar 19, 2024

HealthEquity, Inc. Provides Earnings Guidance for the Fiscal Year Ended January 31, 2024 and Fiscal Year Ending January 31, 2025

Third quarter 2024 earnings released: EPS: US$0.17 (vs US$0.019 loss in 3Q 2023)

HealthEquity, Inc. Provides Earnings Guidance for the Fiscal Year Ending January 31, 2024 and 2025

HealthEquity, Inc. to Report Q3, 2024 Results on Dec 05, 2023

HealthEquity, Inc. (NasdaqGS:HQY) entered into a definitive agreement to acquire BenefitWallet’s Health Savings Account (HSA) portfolio from Conduent Business Services, LLC for $425 million.

Now 21% undervalued

HealthEquity, Inc. Provides Earnings Guidance for the Fiscal Year Ending January 31, 2024

Second quarter 2024 earnings released: EPS: US$0.12 (vs US$0.13 loss in 2Q 2023)

HealthEquity, Inc. to Report Q2, 2024 Results on Sep 05, 2023

HealthEquity, Inc. Announces the Termination of the Employment of Larry Trittschuh, Executive Vice President and Chief Security Officer

Executive VP & CTO recently sold €607k worth of stock

HealthEquity, Inc. Announces Change of CFO

First quarter 2024 earnings released: EPS: US$0.048 (vs US$0.16 loss in 1Q 2023)

HealthEquity, Inc. Provides Earnings Guidance for the Year Ending January 31, 2024

HealthEquity, Inc. to Report Q1, 2024 Results on Jun 05, 2023

Full year 2023 earnings released: US$0.31 loss per share (vs US$0.53 loss in FY 2022)

Now 22% undervalued after recent price drop

Independent Director recently sold €305k worth of stock

HealthEquity, Inc. Provides Earnings Guidance for the Fiscal Year Ending January 31, 2023 and January 31, 2024

Third quarter 2023 earnings released: US$0.019 loss per share (vs US$0.06 loss in 3Q 2022)

HealthEquity, Inc. to Report Q3, 2023 Results on Dec 06, 2022

Independent Director recently sold €312k worth of stock

Independent Director recently sold €1.8m worth of stock

Second quarter 2023 earnings released: US$0.13 loss per share (vs US$0.046 loss in 2Q 2022)

HealthEquity, Inc. Provides Earnings Guidance for the Fiscal Year Ending January 31, 2023

Healthequity, Inc. Elects Paul M. Black to Board of Directors and to Audit and Risk Committee and Talent, Compensation and Culture Committee

HealthEquity, Inc. to Report Q2, 2023 Results on Sep 06, 2022

HealthEquity, Inc. Announces Executive Changes

First quarter 2023 earnings released: US$0.16 loss per share (vs US$0.032 loss in 1Q 2022)

HealthEquity, Inc. Provides Earnings Guidance for the Fiscal Year Ending January 31, 2023

HealthEquity, Inc. to Report Q1, 2023 Results on Jun 06, 2022

HealthEquity, Inc., Annual General Meeting, Jun 23, 2022

HealthEquity, Inc. Expands Board of Directors

Insufficient new directors

HealthEquity, Inc. to Report Q4, 2022 Results on Mar 22, 2022

HealthEquity, Inc. Provides Revenue Guidance for the Fiscal Year 2023

Independent Director recently bought €949k worth of stock

HealthEquity, Inc. Provides Earnings Guidance for the Fiscal Year Ending January 31, 2022

Third quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Independent Director recently sold €462k worth of stock

HealthEquity, Inc. Provides Earnings Guidance for the Fiscal Year Ending January 31, 2022

Second quarter 2022 earnings released: EPS US$0.56 (vs US$0.002 loss in 2Q 2021)

Executive Vice President of Sales William Otten has left the company

Independent Director recently sold €647k worth of stock

Independent Director recently sold €290k worth of stock

Healthequity, Inc. Revises Earnings Guidance for the Fiscal Year Ending January 31, 2022

HealthEquity, Inc. Provides Earnings Guidance for the Fiscal Year Ending January 31, 2022

First quarter 2022 earnings released: US$0.032 loss per share (vs US$0.026 profit in 1Q 2021)

HealthEquity, Inc. (NasdaqGS:HQY) entered into a Custodial Transfer and Asset Purchase Agreement to acquire Health Savings Account Business of Fifth Third Bancorp from Fifth Third Bank, National Association for $60.8 million.

Full year 2021 earnings released: EPS US$0.12 (vs US$0.59 in FY 2020)

Full year 2021 earnings released: EPS US$0.12 (vs US$0.59 in FY 2020)

HealthEquity, Inc. (NasdaqGS:HQY) acquired Luum from Evan McCordick for $67.2 million.

HealthEquity, Inc. to Report Q4, 2021 Results on Mar 15, 2021

HealthEquity, Inc. has completed a Follow-on Equity Offering in the amount of $401.5 million.

New 90-day high: €64.00

Independent Director recently sold €202k worth of stock

Executive Vice President of Sales recently sold €103k worth of stock

Revenue beats expectations

Third quarter 2021 earnings released: EPS US$0.023

Healthequity, Inc. Appoints Stuart Parker as A Member of the Board

HealthEquity, Inc. to Report Q3, 2021 Results on Dec 07, 2020

New 90-day high: €53.50

New 90-day low: €42.60

First half earnings released

HealthEquity, Inc. to Report Q2, 2021 Results on Sep 08, 2020

HealthEquity, Inc. has completed a Follow-on Equity Offering in the amount of $257.6 million.